Small dose of rituximab for graves orbitopathy: new insights into the mechanism of action

Arch Ophthalmol. 2012 Jan;130(1):122-4. doi: 10.1001/archopthalmol.2011.1215.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal, Murine-Derived / administration & dosage*
  • Antibodies, Monoclonal, Murine-Derived / adverse effects
  • Antigens, CD19 / metabolism
  • Antigens, CD20 / metabolism
  • B-Lymphocytes / immunology
  • Female
  • Flow Cytometry
  • Graves Ophthalmopathy / drug therapy*
  • Graves Ophthalmopathy / immunology
  • Humans
  • Immunohistochemistry
  • Immunologic Factors / administration & dosage*
  • Immunologic Factors / adverse effects
  • Lymphocyte Depletion
  • Macrophages / immunology
  • Male
  • Middle Aged
  • Orbital Diseases / drug therapy*
  • Orbital Diseases / immunology
  • Rituximab

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD19
  • Antigens, CD20
  • Immunologic Factors
  • Rituximab